Warning letter
Formulife, Inc.: warning letter of May 12, 2017
FDA warning letter 508605 · Dallas District Office
Key facts
| Reference number | 508605 |
|---|---|
| Company | Formulife, Inc. |
| Subject | CGMP/Dietary Supplement/Adulterated/Misbranded |
| Issue date | May 12, 2017 |
| Posted date | May 23, 2017 |
| Issuing office | Dallas District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101, 101.4, 101.36, 111, 101.2(e), 101.3(d), 101.4(h)(1), 101.9, 101.4(g), 101.9(b), 111.70(b)(2), 111.70(b)(3) and 13 more |
| Inspection city | Allen |
| Inspection ZIP | 75002 |
| Inspection start date | Jul 12, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: